Abstract: A membrane process for the removal of sulfur species from a naphtha feed, in particular, a FCC light cat naphtha, without a substantial loss of olefin yield is disclosed. The process involves contacting a naphtha feed stream with a membrane having sufficient flux and selectivity to separate a sulfur deficient retentate fraction from a sulfur enriched permeate fraction, preferably, under pervaporation conditions. Sulfur deficient retentate fractions are useful directly into the gasoline pool. Sulfur-enriched permeate fractions are rich in sulfur containing aromatic and nonaromatic hydrocarbons and are further treated with conventional sulfur removal technologies, e.g. hydrotreating, to reduce sulfur content. The process of the invention provides high quality naphtha products having a reduced sulfur content and a high content of olefin compounds.

Abstract: The present invention allows for remotely and securely configuring settings for targeted devices within a network with multiple security-trust boundaries. Configuration information is encoded in messages that are digitally signed to ensure the integrity of the configuration information and sent in accordance with a standard messaging transport protocol. By utilizing an already existing port of the standard messaging transport protocol, e.g., SMTP, the number of open ports for configuration purposes is minimized. Further, example embodiments take advantage of hidden fields, i.e., machine readable fields that contain metadata that by default are not presented at a client user interface, for encoding the configuration or command/control information within the messages.

Abstract: The present invention allows for remotely and securely configuring settings for targeted devices within a network with multiple security-trust boundaries. Configuration information is encoded in messages that are digitally signed to ensure the integrity of the configuration information and sent in accordance with a standard messaging transport protocol. By utilizing an already existing port of the standard messaging transport protocol, e.g., SMTP, the number of open ports for configuration purposes is minimized. Further, example embodiments take advantage of hidden fields, i.e., machine readable fields that contain metadata that by default are not presented at a client user interface, for encoding the configuration or command/control information within the messages.

Abstract: The present invention provides for methods, systems, and computer program products for ensuring that sensitive subject matter within electronic messages is not inappropriately transferred between domains with differing security rights. The present invention utilizes the appropriate placement of message transfer agents or servers along with policy documents that include configurable semantics pattern recognition data for identifying deviant messages. Once deviant messages or messages that potentially have sensitive subject matter are identified, the present invention further provides for adaptable actions or remedies for ensuring that the sensitive subject matter is not inappropriately transferred between domains.

Abstract: A flow management system comprising a first panel having a fluid pathway and a second panel having a fluid pathway for passing a second fluid. The fluid pathway of the first panel passes a first fluid. The first panel includes a first compartment to receive a volume of the first fluid. The second panel includes a second compartment to receive a volume of the second fluid. The first and second panels are aligned so that the first compartment overlays the second compartment. The flow management system may be placed within a gap defined by a first surface and a second surface. The first and second compartments are disposed within the gap so that the second compartment bears against the second surface as the second fluid fills the second compartment and forces the first fluid out from the first compartment as the first compartment bears against the first surface.

Abstract: The present invention utilizes honeypots, which are messaging system resources set up to attract unauthorized or illicit use thereof, for automatically identifying messages with malignant content. As messages are received at a honeypot, fingerprints of the messages are generated, which correspond to pattern information within the messages. These fingerprints are then used to determine a confidence level that messages received at a legitimate messaging service are malignant. Based on the confidence level, various actions (e.g., deleting the malignant content) may be executed.

Abstract: This invention relates to a 24 hour extended release dosage formulation and unit dosage form thereof of venlafaxine hydrochloride, an antidepressant, which provides better control of blood plasma levels than conventional tablet formulations which must be administered two or more times a day and further provides a lower incidence of nausea and vomiting than the conventional tablets. More particularly, the invention comprises an extended release formulation of venlafaxine hydrochloride comprising a therapeutically effective amount of venlafaxine hydrochloride in spheroids comprised of venlafaxine hydrochloride, microcrystalline cellulose and, optionally, hydroxypropylmethylcellulose coated with a mixture of ethyl cellulose and hydroxypropylmethylcellulose.

Abstract: This invention relates to a 24 hour extended release dosage formulation and unit dosage form thereof of venlafaxine hydrochloride, an antidepressant, which provides better control of blood plasma levels than conventional tablet formulations which must be administered two or more times a day and further provides a lower incidence of nausea and vomiting than the conventional tablets. More particularly, the invention comprises an extended release formulation of venlafaxine hydrochloride comprising a therapeutically effective amount of venlafaxine hydrochloride in spheroids comprised of venlafaxine hydrochloride, microcrystalline cellulose and, optionally, hydroxypropylmethylcellulose coated with a mixture of ethyl cellulose and hydroxypropylmethylcellulose.

Abstract: This invention relates to a 24 hour extended release dosage formulation and unit dosage form thereof of venlafaxine hydrochloride, an antidepressant, which provides better control of blood plasma levels than conventional tablet formulations which must be administered two or more times a day and further provides a lower incidence of nausea and vomiting than the conventional tablets. More particularly, the invention comprises an extended release formulation of venlafaxine hydrochloride comprising a therapeutically effective amount of venlafaxine hydrochloride in spheroids comprised of venlafaxine hydrochloride, microcrystalline cellulose and, optionally, hydroxypropylmethylcellulose coated with a mixture of ethyl cellulose and hydroxypropylmethylcellulose.

Abstract: This invention relates to a 24 hour extended release dosage formulation and unit dosage form thereof of venlafaxine hydrochloride, an antidepressant, which provides better control of blood plasma levels than conventional tablet formulations which must be administered two or more times a day and further provides a lower incidence of nausea and vomiting than the conventional tablets. More particularly, the invention comprises an extended release formulation of venlafaxine hydrochloride comprising a therapeutically effective amount of venlafaxine hydrochloride in spheroids comprised of venlafaxine hydrochloride, microcrystalline cellulose and, optionally, hydroxypropylmethylcellulose coated with a mixture of ethyl cellulose and hydroxypropylmethylcellulose.

Abstract: This invention relates to a 24 hour extended release dosage formulation and unit dosage form thereof of venlafaxine hydrochloride, an antidepressant, which provides better control of blood plasma levels than conventional tablet formulations which must be administered two or more times a day and further provides a lower incidence of nausea and vomiting than the conventional tablets. More particularly, the invention comprises an extended release formulation of venlafaxine hydrochloride comprising a therapeutically effective amount of venlafaxine hydrochloride in spheroids comprised of venlafaxine hydrochloride, microcrystalline cellulose and, optionally, hydroxypropylmethylcellulose coated with a mixture of ethyl cellulose and hydroxypropylmethylcellulose.

Abstract: This invention relates to a 24 hour extended release dosage formulation and unit dosage form thereof of venlafaxine hydrochloride, an antidepressant, which provides better control of blood plasma levels than conventional tablet formulations which must be administered two or more times a day and further provides a lower incidence of nausea and vomiting than the conventional tablets. More particularly, the invention comprises an extended release formulation of venlafaxine hydrochloride comprising a therapeutically effective amount of venlafaxine hydrochloride in spheroids comprised of venlafaxine hydrochloride, microcrystalline cellulose and, optionally, hydroxypropylmethylcellulose coated with a mixture of ethyl cellulose and hydroxypropylmethylcellulose.

Abstract: This invention relates to a 24 hour extended release dosage formulation and unit dosage form thereof of venlafaxine hydrochloride, an antidepressant, which provides better control of blood plasma levels than conventional tablet formulations which must be administered two or more times a day and further provides a lower incidence of nausea and vomiting than the conventional tablets. More particularly, the invention comprises an extended release formulation of venlafaxine hydrochloride comprising a therapeutically effective amount of venlafaxine hydrochloride in spheroids comprised of venlafaxine hydrochloride, microcrystalline cellulose and, optionally, hydroxypropylmethylcellulose coated with a mixture of ethyl cellulose and hydroxypropylmethylcellulose.

Abstract: A membrane process for the removal of sulfur species from a naphtha feed, in particular, a FCC light cat naphtha, without a substantial loss of olefin yield is disclosed. The process involves contacting a naphtha feed stream with a membrane having sufficient flux and selectivity to separate a sulfur deficient retentate fraction from a sulfur enriched permeate fraction, preferably, under pervaporation conditions. Sulfur deficient retentate fractions are useful directly into the gasoline pool. Sulfur-enriched permeate fractions are rich in sulfur containing aromatic and nonaromatic hydrocarbons and are further treated with conventional sulfur removal technologies, e.g. hydrotreating, to reduce sulfur content. The process of the invention provides high quality naphtha products having a reduced sulfur content and a high content of olefin compounds.

Abstract: This invention relates to a 24 hour extended release dosage formulation and unit dosage form thereof of venlafaxine hydrochloride, an antidepressant, which provides better control of blood plasma levels than conventional tablet formulations which must be administered two or more times a day and further provides a lower incidence of nausea and vomiting than the conventional tablets. More particularly, the invention comprises an extended release formulation of venlafaxine hydrochloride comprising a therapeutically effective amount of venlafaxine hydrochloride in spheroids comprised of venlafaxine hydrochloride, microcrystalline cellulose and, optionally, hydroxypropylmethylcellulose coated with a mixture of ethyl cellulose and hydroxypropylmethylcellulose.

Abstract: An absorbent body enclosed between a liquid-permeable liner sheet layer and a liquid-impermeable backsheet layer is disclosed. The article has a longitudinal axis, a relatively wide anterior end and an opposite posterior end connected by side margins to define a generally triangular shape. The side margins substantially continuously converge to the posterior end, and at least one tab extends from each side margin. There is at least one attachment element aligned oblique to the longitudinal axis of the article that is associated with each tab. A method and apparatus are also disclosed.

Abstract: Method, system and computer program product for converting integers to floating point values in a data processing system. The method utilizes data flow analysis and control flow analysis to recognize that a particular integer that is to be converted contains only a limited range of values. Knowledge of this limited range is used to establish a table of floating point values indexed by the integer value. By using the table of floating point values, conversion of an integer to a floating point value can be performed faster and with reduced memory traffic.

Abstract: The invention is a bracket for installing a gutter cover for ducting rainwater to a rainwater gutter, where the gutter cover prevents debris from entering the gutter. The bracket is roughly shaped like three extended fingers, where each finger is a strut. The struts converge at a junction. The various struts are a lifting strut that supports the leading hooked frontal edge of a gutter cover, a stabilizing strut that has a hooked end that interlocks with the hooked edge of a frontal rim of a gutter trough, and a bracing strut that is a leg stemming from the junction to a bottom portion of the gutter.

Abstract: A flow management system for extracorporeal blood treatment application helps to ensure proper balance of incoming and outgoing fluids by precise balancing of relatively small balance chambers. The invention employs combinations of features that help to ensure accuracy including underfilling of the waste flow side of a fixed volume chamber and mechanical connections to synchronize valves and pumps.

Abstract: Isolation and amplification of cardiac pacemaking/conduction system cells and development of a pacemaking/conduction system in vitro using the expression of surrogate expression markers. Use of markers to identify and select for clusters of pacemaking “nodes” that are functionally coupled with adjacent contracting regions and generation of cell populations displaying electrical properties characteristic of specialized pacemaking/conducting cardiac myocytes for modeling the cardiac conduction system, testing of pharmaceuticals and for transplantation.